CA-BIOCYTOGEN
30.8.2022 02:01:34 CEST | Business Wire | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen") and TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), today jointly announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for the initiation of a Phase 1/2 clinical study of YH001 in combination with envafolimab and doxorubicin for the treatment of sarcoma patients, including patients who have not received prior therapy.
The Phase 1/2 trial will assess the safety and efficacy of YH001 and envafolimab in patients with the rare sarcoma subtypes of alveolar soft part sarcoma and chondrosarcoma and assess the safety and efficacy of the combination of YH001, envafolimab and doxorubicin in the common sarcoma subtypes of leiomyosarcoma and dedifferentiated liposarcoma.
“YH001 was discovered using Biocytogen’s evidence-based in vivo drug efficacy screening platform and has demonstrated a favorable safety profile and promising anti-tumor activity in combination with a PD-1 antibody in an earlier phase 1 clinical study,” said Rong Chen, M.D., Ph.D., VP of Biocytogen, CEO and CMO of Eucure Biopharma. “As an antibody targeting the validated checkpoint CTLA-4, YH001 is expected to play a very important role in immune-oncology therapy. We are glad to learn that the combination therapy of YH001 + envafolimab and doxorubicin received IND approval by the FDA.”
“We are pleased to receive approval from the FDA to initiate our triplet combination therapy study in sarcoma, which includes our potentially best-in-class CTLA-4 antibody YH001 and the only subcutaneous checkpoint inhibitor approved anywhere in the world, envafolimab,” said Charles Theuer, M.D., Ph.D., TRACON’s Chief Executive Officer. “We look forward to enrolling patients in this study and giving patients additional options for their sarcoma treatment.”
About YH001
YH001 is an IgG1 antibody targeting CTLA-4 that was invented by Biocytogen, the parent company of Eucure Biopharma, and licensed by TRACON. YH001 has shown enhanced antibody dependent cellular cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC) in vitro when compared with ipilimumab. In preclinical studies YH001 demonstrated superior T cell activation and superior tumor growth inhibition activity compared to ipilimumab as a single agent and when combined with a PD-(L)1 antibody in human transgenic mouse tumor models. In these models, single agent YH001 depleted regulatory T cells and increased CD8+ T cells in tumor tissue. YH001 has been dosed as a single agent in a Phase 1 trial in China (NCT04699929) and in combination with the PD-1 antibody toripalimab in a Phase 1 trial in Australia (NCT04357756).
About Eucure Biopharma
As a wholly owned subsidiary of Biocytogen, Eucure Biopharma undertakes the mission of clinical development for Biocytogen’s R&D pipelines. Relying on a strong clinical development team and extensive clinical development experience, Eucure Biopharma focuses on antibody drug therapy for oncology and other indications. The company has established a product pipeline for more than 10 targets, with two products in launched phase II multi-regional clinical trials (MRCT) and two in phase I. For details, please visit www.eucure.com.
About Biocytogen
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Using its proprietary RenMabTM /RenLite® mice platforms for fully human monoclonal and bispecific antibody development, Biocytogen has integrated its in vivo drug efficacy screening platforms and strong clinical development expertise to streamline the entire drug development process. Biocytogen is undertaking a large-scale project to develop antibody drugs for more than 1000 targets, known as Project Integrum, and has entered ongoing collaborations with dozens of partners worldwide to produce a variety of antibody drugs. The company's pipeline includes 12 core products, among which two products are in phase II multi-regional clinical trials and two products are in phase I. Headquartered in Beijing, Biocytogen has branches in Haimen Jiangsu, Shanghai and Boston, USA. For more information, please visit www.biocytogen.com.cn.
About TRACON
TRACON is a clinical-stage biopharmaceutical company utilizing a cost-efficient, CRO-independent, product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies. The Company’s clinical-stage pipeline includes: Envafolimab, a PD-L1 single-domain antibody given by rapid subcutaneous injection that is being studied in the pivotal ENVASARC trial for sarcoma; YH001, a potential best-in-class CTLA-4 antibody in Phase 1 development; TRC102, a Phase 2 small molecule drug candidate for the treatment of lung cancer; and TJ004309, a CD73 antibody in Phase 1 development for the treatment of advanced solid tumors. TRACON is actively seeking additional corporate partnerships through a profit-share or revenue-share partnership, or through franchising TRACON’s product development platform. TRACON believes it can serve as a solution for companies without clinical and commercial capabilities in the United States or who wish to become CRO-independent. To learn more about TRACON and its product pipeline, visit TRACON’s website at www.traconpharma.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220829005548/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
MBRYONICS Announces Further Expansion in Its Customer Base and Manufacturing Facilities to Meet Rapidly Growing Demand20.4.2026 09:00:00 CEST | Press release
MBRYONICS has been expanding its partner and customer ecosystem and has recently been selected by the European Space Agency (ESA) for in-orbit demonstration activities in a team led by Kepler Communications. The €18.6M award is under Element 3 of the High-throughput Optical Network (HydRON) program, a project under ESA’s Optical and Quantum Communications – ScyLight program, within the agency’s Advanced Research in Telecommunications Systems (ARTES). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260420035633/en/ MBRYONICS was chosen to be part of this mission following its successful contribution to HydRON Element 2, where the company delivered optical testbed facilities to provide system reliability. In collaboration with Kepler Communications for Element 3, MBRYONICS optical terminal (StarCom), and its ground station test bed, have been selected to demonstrate full interoperability with other optical terminal providers du
Echodyne Named as Radar System for Trust Automation’s $490M Air Force Counter-UAS Engineering Contract20.4.2026 09:00:00 CEST | Press release
EchoShield® radar integrated into Small-Unmanned Air Defense System (SUADS) to deliver on $490M Air Force IDIQ Echodyne, the radar platform company, today announces its inclusion as a primary radar system within Trust Automation’s Small-Unmanned Air Defense System (SUADS) Counter-UAS platform, to be delivered to the U.S. Air Force under a $490M IDIQ contract announced in August 2025. Rapidly Deployable Small-Unmanned Air Defense System (RD-SUADS), Fixed Site Small-Unmanned Air Defense System (FS-SUADS), and Expeditionary Small-Unmanned Air Defense System (EX-SUADS) platforms adhere to the Sensor Open Systems Architecture (SOSA) standard with EchoShield radars being the first fully integrated SOSA solution in the platform. The RD-SUADS platform is a self-contained, self-powered C-UAS system fitted to standard pallet sizes for easy transport via military aircraft, while the FS-SUADS is for deployment at permanent military installations and can be integrated as a group or standalone for d
QAD | Redzone Brings the Future of Agentic AI in Manufacturing to Hannover Messe 202620.4.2026 08:00:00 CEST | Press release
The company will showcase how agentic AI is driving real-time execution so manufacturers can operate faster, adapt continuously and deliver measurable business outcomes. QAD | Redzone, the company redefining manufacturing and supply chains through intelligent, adaptive solutions, will showcase its AI-powered manufacturing platform that empowers the entire workforce, from the top floor to the shop floor, at Hannover Messe 2026, taking place April 20-24 in Hannover, Germany. At this year’s event, QAD | Redzone will show how manufacturing is entering a new phase where AI turns traditional systems of record into systems of action, empowering manufacturers to move from fragmented systems and delayed decisions to real-time, coordinated execution across the business. “Manufacturers don’t have a data problem, they have an execution problem,” said Sanjay Brahmawar, CEO at QAD | Redzone. “With agentic AI, we can create unprecedented visibility, but the value will only be realized when that intel
SymphonyAI Launches Eight AI Applications Purpose-Built for Energy Asset Reliability and Operational Performance20.4.2026 07:09:00 CEST | Press release
Eight AI applications engineered for asset reliability, operational performance, and emissions obligations SymphonyAI, a global leader in Vertical AI platforms, today announced eight new industrial AI applications purpose-built for energy operators, marking the most targeted expansion of IRIS Foundry into the energy sector to date. Unlike generic asset management software, these applications are engineered around the specific failure modes, process dynamics, and regulatory obligations of energy and resources operations — compressor surge, heat exchanger fouling, pipeline integrity degradation, refinery unit yield loss, and the growing compliance burden of EU methane regulation and emissions reporting. By combining SymphonyAI’s deep industrial ontology with IRIS Foundry’s ability to unify IT, OT, and IoT data from historians, SCADA systems, inspection databases, and enterprise platforms into a single governed intelligence layer, the new suite delivers causal AI at the point where energy
Petronor and H2SITE Partner to Pioneer High-Purity Hydrogen Production in Refining Through Advanced Membrane Technology20.4.2026 07:00:00 CEST | Press release
H2SITE, a technology company specialised in advanced hydrogen production and separation solutions, has signed a strategic agreement with Petronor, a leading refinery and key industrial player in the energy sector with a clear commitment to achieving net-zero emissions, to deploy its high-efficiency hydrogen separation technology at Petronor’s refinery. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260419792308/en/ The partnership sets the stage for the joint development of a pioneering First-of-a-Kind (FOAK) unit, integrating H2SITE’s proprietary membrane technology into the Steam Methane Reforming (SMR) process in refineries to improve overall plant efficiency, enhance CO₂ capture opportunities, and ultimately strengthen operational performance and industrial competitiveness. Petronor’s engineering and operations teams are joining forces with H2SITE’s technical experts, leveraging decades of refinery expertise, industrial
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom